Camlin Fine Sciences Limited has informed the Exchange about change in Management
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.0 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Camlin Fine Sciences reported Q1FY26 results with standalone revenue of Rs. 191.4 crore, up 5% YoY, and a net loss of Rs. 10.68 crore versus Rs. 13.68 crore loss in Q1FY25. Consolidated revenue rose 11% YoY to Rs. 423.6 crore with a narrower net loss of Rs. 6.43 crore. The board approved the re-appointment of Mr. Joseph Conrad D'Souza as a Non-Executive Independent Director for a second 5-year term from September 29, 2025, subject to shareholder approval via postal ballot. Mr. Hari Rajmohan was appointed as an Alternate Director to a non-executive director for August 8, 2025. Mr. Amarsinh Jadhavrao, Chief Executive (HR & Corporate Affairs), resigned, and the CFO Mr. Santosh Parab was given interim ad hoc charge of the HR and Administration department until a successor is appointed.
The Q1 numbers show modest top-line growth but persistent losses on both standalone and consolidated bases, keeping sentiment cautious. The KMP-level exit in HR is being managed internally by the CFO, limiting disruption, while the re-appointment of a seasoned independent director supports board continuity.